WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 585117
Description: S 15931 antagonizes postsynaptic 5-HT(1A) receptors and is an agonist for 5-HT(1A) autoreceptors.
MedKoo Cat#: 585117
Name: S 15931
Chemical Formula: C23H28N2O2
Exact Mass: 364.2151
Molecular Weight: 364.489
Elemental Analysis: C, 75.79; H, 7.74; N, 7.69; O, 8.78
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: S 15931; S15931; S-15931
IUPAC/Chemical Name: Piperazine, 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-(2-(2,3-dihydro-1H-inden-1-yl)ethyl)-
InChi Key: OARKPUCUFAIZCW-UHFFFAOYSA-N
InChi Code: InChI=1S/C23H28N2O2/c1-2-5-20-18(4-1)8-9-19(20)10-11-24-12-14-25(15-13-24)21-6-3-7-22-23(21)27-17-16-26-22/h1-7,19H,8-17H2
SMILES Code: N1(C2=C3OCCOC3=CC=C2)CCN(CCC4CCC5=C4C=CC=C5)CC1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 364.489 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Millan MJ, Seguin L, Honoré P, Girardon S, Bervoets K. Pro- and antinociceptive actions of serotonin (5-HT)1A agonists and antagonists in rodents: relationship to algesiometric paradigm. Behav Brain Res. 1996;73(1-2):69-77. PubMed PMID: 8788480.
2: Schreiber R, Brocco M, Lefèbvre de Ladonchamps B, Monneyron S, Millan MJ. A drug discrimination analysis of the actions of novel serotonin1A receptor ligands in the rat using the 5-HT1A receptor agonist, 8-hydroxy-2-(di-n-propylamino)tetralin. J Pharmacol Exp Ther. 1995 Nov;275(2):822-31. PubMed PMID: 7473172.
3: Gobert A, Lejeune F, Rivet JM, Audinot V, Newman-Tancredi A, Millan MJ. Modulation of the activity of central serotoninergic neurons by novel serotonin1A receptor agonists and antagonists: a comparison to adrenergic and dopaminergic neurons in rats. J Pharmacol Exp Ther. 1995 Jun;273(3):1032-46. PubMed PMID: 7791073.
4: Millan MJ, Canton H, Gobert A, Lejeune F, Rivet JM, Bervoets K, Brocco M, Widdowson P, Mennini T, Audinot V, et al. Novel benzodioxopiperazines acting as antagonists at postsynaptic 5-HT1A receptors and as agonists at 5-HT1A autoreceptors: a comparative pharmacological characterization with proposed 5-HT1A antagonists. J Pharmacol Exp Ther. 1994 Jan;268(1):337-52. PubMed PMID: 8301575.